Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private ...

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980 ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to ...

Developed by Valneva SE, the single-dose vaccine is authorised for use in individuals aged 18 and older. GlutenID, developed by California-based Targeted Genomics, is approved by US regulators – ...

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to ...

Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming ...

(MENAFN- GlobeNewsWire - Nasdaq) Saint-Herblain (France), March 3, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will ...

Saint-Herblain (France), March 3, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that its senior management will participate at upcoming investor ...